Why the study?
Does rivaroxaban reduce hospital visit costs in adult patients with deep vein thrombosis compared to LMWH/warfarin?
Does rivaroxaban reduce hospital visit costs in adult patients with deep vein thrombosis compared to LMWH/warfarin?
Rivaroxaban use is associated with significantly lower index and subsequent hospital visit costs compared to LMWH/warfarin in patients with deep vein thrombosis.
No takes yet. Share an insight, caveat, or question.
Lower costs with rivaroxaban in DVT; extends economic observations but leaves open need for randomized confirmation.
Merli et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: